Drug Delivery System to Save Hearing During Pediatric Chemotherapy Regimens. POP 09/19/17 - 06/18/18.

Otomagnetics发明了一种磁性药物输送装置，我们打算开发这种装置，以防止儿童化疗的主要副作用。顺铂和卡铂化疗方案可导致严重的听力损失，特别是在儿科患者中。对于顺铂，听力损失被FDA列为标签上的剂量限制性毒性。儿童的听力损失对他们的沟通和学习能力有着巨大的影响，并与大量的认知和言语发育缺陷有关。Otomagnetics的药物输送技术能够对耳蜗进行耳保护治疗，在动物研究中已显示可以从顺铂方案中挽救听力。局部和非侵入性磁性递送小剂量的耳保护类固醇到耳蜗不会中断化疗的全身抗肿瘤作用，并且在一些患者中，由于诱导的严重听力损失，将消除对施用所需化疗剂量的限制。

Otomagnetics has invented a magnetic drug delivery device that we intend to develop to enable prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin chemotherapy regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing loss in kids has a dramatic impact on their ability to communicate and learn and is associated with substantial cognitive and speech development deficits. Otomagnetics' drug delivery technology enables topical delivery of otoprotective therapy to the cochlea, and in animal studies has been shown to save hearing from cisplatin regimens. Topical and non-invasive magnetic delivery of a small dose of otoprotective steroid to the cochlea would not interrupt the systemic anti-tumor action of chemotherapy, and in some patients would remove limits on administering needed chemo doses due to induced severe hearing loss.